USABiotech & Genomic Medicine
Neurocrine Posts KINECT-PRO Data as Revenue Jumps 39%
Neurocrine Biosciences on August 12 published KINECT-PRO Phase 4 findings showing INGREZZA eased the daily burden of tardive dyskinesia beyond what clinician rating scales capture. The study followed 59 tardive dyskinesia patients on daily INGREZZA for 24 weeks, with 52 reaching the final visit; among the 45 patients in the efficacy analysis, about 58% hit the threshold for symptomatic remission on clinician-rated movement severity, with gains exceeding the clinically meaningful threshold by Week 4 on movement severity and by Week 8 on patient-reported impact. The data landed weeks after Neurocrine's July 30 second-quarter report, which showed total revenue up 39% year over year to $959 million and INGREZZA sales climbing 15% to $716 million on record new prescriptions, prompting management to raise full-year INGREZZA guidance to $2.825 billion to $2.875 billion. CRENESSITY and the newly acquired VYKAT XR added $184 million and $54 million respectively. The growth came at a cost: cash and marketable securities fell from roughly $2.5 billion at the end of 2025 to about $482 million by June 30, largely because Neurocrine paid $53.00 a share in cash to acquire Soleno Therapeutics in a $2.9 billion deal that closed in May, backstopped by a new $1.0 billion revolving credit facility. Second-quarter R&D rose to $327 million from $244 million a year earlier, SG&A jumped to $440 million from $286 million, and the Soleno deal added roughly $2.2 billion of intangible assets that will amortize over 16 years, while INGREZZA still supplied about three-quarters of quarterly revenue.